On October 14 the FDA announced a Rare Disease Framework Initiative and a white paper, "A New Framework for Rare Disease Review". Trade coverage reports the agency's own starting point: as of 2025, only about 5% of recognized rare diseases had an FDA-approved treatment. A public meeting is set for October 28.

The first question a reader should ask is whether rare disease is already a minor corner of FDA's work. It is not.

How much of FDA's output is already rare disease?

About half of it. CDER, the FDA center that reviews most new drugs, reports how many of its novel approvals each year carried an orphan drug designation, the status given to drugs for conditions that affect fewer than 200,000 people in the US.

Orphan-designatedNot orphan-designated

Source: FDA CDER, Advancing Health Through Innovation: New Drug Therapy Approvals reports, 2019 and 2021 to 2025. CDER only; biologics reviewed by CBER, such as gene therapies, are not included. The "other" column is total approvals minus the reported orphan count. 2020 is left out because we could not open that report. FDA notes that not every drug for a rare disease carries orphan designation.

View data

year	orphan	other
2019	21	27
2021	26	24
2022	20	17
2023	28	27
2024	26	24
2025	23	23

Over the six reported years, 144 of 286 novel approvals were orphan-designated, an average of 24 a year. The 2019 share was 43.8%. Since 2021 it has stayed within a band of about four points (50.0% to 54.1%). Our earlier post on the record 2026 approval pace counted approvals but not their designations, so we do not know the 2026 split yet.

Why does 5% coexist with 50%?

Because the two numbers count different things. The chart counts drugs approved in a year. The 5% counts diseases that have at least one approved treatment. A single approval can cover one condition or several, and several approvals can target the same disease, which is common in rare cancers and in conditions that already have a treatment. You cannot divide one number by the other to estimate how long coverage would take.

What the pair does show is that rare disease is already half of the approvals flow while most rare conditions still have no approved treatment. The FDA presents that gap as the reason to change how rare-disease evidence is reviewed.

What does the framework actually change today?

Nothing in the rules yet. As described by the FDA Law Blog and trade press, the initiative covers pre-IND engagement through post-approval obligations, including manufacturing (CMC) review and pre-approval inspections. It lists possible work: considering regulations that make tailored evidence standards the default, reviewing guidance on endpoints, statistics and trial design, wider use of outside experts, and reviewer training. The statutory standard of safety and effectiveness is described as unchanged.

So the October 28 meeting and whatever guidance follows are the things to watch. For a company with a rare-disease program, the practical questions are which endpoints become acceptable, how small a trial can be, and how much manufacturing evidence is needed before approval.

What this does and does not show

The chart shows how many approvals carried orphan designation, not how many patients gained a first treatment. The 5% figure comes from FDA via news coverage; we could not open the white paper itself, which was not reachable from our tools, so the definition of "recognized rare disease" and the exact count are not verified here. Orphan designation is also a regulatory status, not a measure of unmet need. Finally, the chart covers CDER only.

Sources

1. FDA CDER, New Drug Therapy Approvals 2025: 23 of 46 novel approvals with orphan designation.
2. FDA CDER, New Drug Therapy Approvals 2024: 26 of 50. 2023: 28 of 55. 2022: 20 of 37. 2021: 26 of 50. 2019: 21 of 48.
3. RAPS, FDA launches Rare Disease Framework Initiative, October 15, 2026: the 5% figure, the October 28 workshop. Secondary source for the white paper.
4. European Pharmaceutical Review, FDA seeks feedback on new framework for rare disease drug development: the 5% figure, possible guidance and regulation changes.
5. FDA Law Blog, Rare Disease Refresh: FDA's Rare Disease Framework Initiative, October 14, 2026: scope and planned actions.
6. FDA, Rare Disease Framework Initiative public meeting, October 28, 2026.
7. Our earlier analysis: FDA has approved 46 novel drugs by October 9.